BRAF and central nervous system cancer: The role of vemurafenib in BRAF V600-mutant gliomas has been investigated in the VE-BASKET trial [82], which evaluated 24 patients (six GBM, five anaplastic astrocytoma, one high grade glioma not otherwise specified, and twelve with other histologies).